Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | FOS | P01100 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20629004 | 0.93 | PLA2G4A (0.42) | PLA2G4AFOSJUNALDH1A1MAPT | |
| SCHEMBL15057589 | 0.92 | PLA2G4A (0.42) | PLA2G4AFOSJUNALDH1A1MAPT | |
| SCHEMBL15057237 | 0.91 | RORC (0.42) | PLA2G4AFOSJUNALDH1A1MAPT | |
| SCHEMBL15057507 | 0.91 | EPHX2 (0.38) | FOSJUNALDH1A1MAPTPKM | |
| SCHEMBL15057343 | 0.87 | ALDH1A1 (0.41) | PLA2G4AFOSJUNALDH1A1MAPT | |
| SCHEMBL15076168 | 0.86 | PTGER1 (0.44) | PLA2G4AALDH1A1MAPTPKMTSHR | |
| SCHEMBL15076165 | 0.86 | PTGER1 (0.53) | PTGER1 | |
| SCHEMBL15076249 | 0.85 | PTGER1 (0.41) | PLA2G4AALDH1A1MAPTPKMTSHR | |
| SCHEMBL20628878 | 0.84 | PTGER1 (0.40) | PLA2G4AALDH1A1MAPTPKMTSHR | |
| SCHEMBL15057997 | 0.83 | PTGER1 (0.40) | PLA2G4AALDH1A1MAPTPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | claimed |
| EP-3424904-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | Allergan, Inc. (US) | 2019-01-09 | — | — | EP | claimed |
| EP-2794561-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | claimed |
| EP-2794561-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-10-29 | — | — | EP | claimed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2794561-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885FOS 1499/4885JUN 655/4885 |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885FOS 1499/4885JUN 655/4885 |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885FOS 1499/4885JUN 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.